SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-372445"
 

Search: onr:"swepub:oai:DiVA.org:uu-372445" > SCOT :

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006891naa a2200733 4500
001oai:DiVA.org:uu-372445
003SwePub
008190107s2018 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3724452 URI
0247 a https://doi.org/10.1038/s41416-018-0319-z2 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Robles-Zurita, Joseu Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland4 aut
2451 0a SCOT :b a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
264 c 2018-11-13
264 1b Springer Science and Business Media LLC,c 2018
338 a print2 rdacarrier
520 a BACKGROUND: The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer.METHODS: In total, 6088 patients with fully resected high-risk stage II or stage III colorectal cancer were randomised and followed up for 3-8 years. The within-trial cost-effectiveness analysis from a UK health-care perspective is presented using the resource use data, quality of life (EQ-5D-3L), time on treatment (ToT), disease-free survival after treatment (DFS) and overall survival (OS) data. Quality-adjusted partitioned survival analysis and Kaplan-Meier Sample Average Estimator estimated QALYs and costs. Probabilistic sensitivity and subgroup analysis was undertaken.RESULTS: The 3M arm is less costly (-4881; pound 95% CI: -6269; pound -3492) pound and entails (non-significant) QALY gains (0.08; 95% CI: -0.086; 0.230) due to a better significant quality of life. The net monetary benefit was significantly higher in 3M under a wide range of monetary values of a QALY. The subgroup analysis found similar results for patients in the CAPOX regimen. However, for the FOLFOX regimen, 3M had lower QALYs than 6M (not statistically significant).CONCLUSIONS: Overall, 3M dominates 6M with no significant detrimental impact on QALYs. The results provide the economic case that a 3M treatment strategy should be considered a new standard of care.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Boyd, Kathleen A.u Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland4 aut
7001 a Briggs, Andrew H.u Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland4 aut
7001 a Iveson, Timothyu Southampton Univ Hosp NHS Fdn Trust, Southampton, Hants, England4 aut
7001 a Kerr, Rachel S.u Univ Oxford, Dept Oncol, Oxford, England4 aut
7001 a Saunders, Mark P.u Christie Hosp, Manchester, Lancs, England4 aut
7001 a Cassidy, Jimu Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland4 aut
7001 a Hollander, Niels Henriku Zealand Univ Hosp, Dept Oncol & Palliat Care, Radmandsengen 5, DK-4700 Naestved, Denmark4 aut
7001 a Tabernero, Josepu Univ Autonoma Barcelona, CIBERONC, Vall dHebron Univ Hosp, Barcelona, Spain;Univ Autonoma Barcelona, CIBERONC, Inst Oncol VHIO, Barcelona, Spain4 aut
7001 a Segelov, Evau Australasian Gastrointestinal Trials Grp AGITG, Melbourne, Vic, Australia;Monash Univ, Melbourne, Vic, Australia;Monash Hlth, Melbourne, Vic, Australia4 aut
7001 a Glimelius, Bengtu Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)bengglim
7001 a Harkin, Andreau Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland4 aut
7001 a Allan, Karenu Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland4 aut
7001 a McQueen, Johnu Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland4 aut
7001 a Pearson, Sarahu Univ Oxford, OCTO, Dept Oncol, Oxford, England4 aut
7001 a Waterston, Ashitau Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland4 aut
7001 a Medley, Louiseu Royal United Hosp, Bath, Avon, England4 aut
7001 a Wilson, Charlesu Addenbrookes Hosp, Cambridge, England4 aut
7001 a Ellis, Richardu Royal Cornwall Hosp NHS Trust, Truro, Cornwall, England4 aut
7001 a Essapen, Sharadahu Royal Surrey Cty Hosp NHS Fdn Trust, St Lukes Canc Ctr, Guildford, Surrey, England4 aut
7001 a Dhadda, Amandeep S.u Castle Hill Hosp, Kingston Upon Hull, N Humberside, England4 aut
7001 a Hughes, Robu Mt Vernon Canc Ctr, Northwood, Middx, England4 aut
7001 a Falk, Stephenu Bristol Canc Inst, Bristol, Avon, England4 aut
7001 a Raouf, Sherifu Barking Havering & Redbridge Univ Hosp NHS Trust, Barking, England4 aut
7001 a Rees, Charlotteu Southampton Univ Hosp NHS Fdn Trust, Southampton, Hants, England4 aut
7001 a Olesen, Rene K.u Zealand Univ Hosp, Dept Oncol & Palliat Care, Radmandsengen 5, DK-4700 Naestved, Denmark4 aut
7001 a Propper, Davidu Queen Mary Univ London, Barts Canc Inst, London, England4 aut
7001 a Bridgewater, Johnu UCL, London, England4 aut
7001 a Azzabi, Ashrafu Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England4 aut
7001 a Farrugia, Davidu Cheltenham Gen Hosp, Gloucestershire Oncol Ctr, Cheltenham, Glos, England4 aut
7001 a Webb, Andrewu Brighton & Sussex Univ Hosp Trust, Brighton, E Sussex, England4 aut
7001 a Cunningham, Davidu Royal Marsden, London, England4 aut
7001 a Hickish, Tamasu Bournemouth Univ, Poole Hosp, Bournemouth, Dorset, England4 aut
7001 a Weaver, Andrewu Oxford Univ Hosp Fdn Trust, Churchill Hosp, Oxford, England4 aut
7001 a Gollins, Simonu North Wales Canc Treatment Ctr, Rhyl, Wales4 aut
7001 a Wasan, Harpreet S.u Imperial Coll London, Hammersmith Hosp, London, England4 aut
7001 a Paul, Jamesu Univ Glasgow, Inst Canc Sci, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland4 aut
7102 a Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotlandb Southampton Univ Hosp NHS Fdn Trust, Southampton, Hants, England4 org
7730 t British Journal of Cancerd : Springer Science and Business Media LLCg 119:11, s. 1332-1338q 119:11<1332-1338x 0007-0920x 1532-1827
8564 u https://www.nature.com/articles/s41416-018-0319-z.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-372445
8564 8u https://doi.org/10.1038/s41416-018-0319-z

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view